Providence St. Patrick Hospital’s International Heart Institute structural heart interventional team completed their first Tendyne procedure on May 3. Congratulations to Drs. Dan Spoon, Michael Reed, Todd Maddux and Joe Schmoker and their team for a successful first mitral valve interventional procedure in Missoula, Montana, once again! The patient is doing very well.
The Tendyne valve is a first-of-its-kind therapy to replace the mitral valve in patients in need of heart failure symptom relief and quality-of-life improvement without open heart surgery and when transcatheter mitral repair is not possible due to high surgical risk. This life-changing therapy treats significant mitral regurgitation in patients requiring a heart valve replacement.
As the most common heart disease affecting the heart valves, mitral regurgitation is a debilitating, progressive and life-threatening condition in which the heart's mitral valve does not close completely, allowing blood to flow backward into the left atrium of the heart.
For patients at high-risk for open-heart surgery or in clinical situations when the mitral valve is too damaged for a successful repair with the MitraClip device, the Tendyne offers a much-needed, alternative minimally invasive treatment option when the leaky valve needs to be replaced.
Global trial results to date have proven excellent procedural safety and have shown 98.9% of Tendyne patients experienced MR elimination at discharge which was sustained through one-year in this extremely sick patient group.
The self-expanding valve is delivered through a small incision in the chest and up through the heart where it is implanted in a beating heart, replacing the person's native mitral valve. The Tendyne valve is available in multiple sizes to treat a broad range of valve anatomies.
The Tendyne is an investigational device in the U.S. The International Heart Institute is only one of 74 places in the U.S. that are part of this life-saving research This randomized controlled trial will provide the opportunity to evaluate the safety and clinical benefits of the Tendyne valve compared to the MitraClip in patients with symptomatic, moderate-to-severe, or severe mitral regurgitation.
About the AuthorMore Content by Providence News Team